Human Papilloma Virus (HPV-16) luismmolina/iStock via Getty Images On Friday April 19th, shares of Hookipa Pharma (NASDAQ:HOOK) closed at $0.733/s with a valuation ~$72.53M. To be clear, this company is a High Risk/High Reward play and as such, is probably not a suitable investment for most investor’s portfolios. Typically, I would build a 2% position at most in my portfolio for this type of early clinical development target when I am interested. However, in this particular situation, I have increased my ...